Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: A meta-analysis and systematic review

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 925-933

  Chen, Yen Wen ^a   Lin, Pao Yen ^b,c   Tu, Kun Yu ^d   Cheng, Yu Shian ^d   Wu, Ching Kuan ^d   Tseng, Ping Tao ^d  

^a E DA HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d Tsyr Huey Mental Hospital   (Taiwan)

Author keywords

Mood disorder; Neurotrophic factor; NGF; Psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT; NERVE GROWTH FACTOR;

AGE; ARTICLE; BECK DEPRESSION INVENTORY; DISEASE COURSE; DISEASE SEVERITY; DSM-III-R; DSM-IV; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW;

EID: 84929149931     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S81432     Document Type: Article

References (56)

1. Aloe L, Levi-Montalcini R. Nerve growth factor induced overgrowth of axotomized superior cervical ganglia in neonatal rats. Similarities and differences with NGF effects in chemically axotomized sympathetic ganglia. Arch Ital Biol. 1979;117(4):287-307.
2. Levi-Montalcini R, Calissano P. The nerve-growth factor. Sci Am. 1979;240(6):68-77.
3. Aloe L, Levi-Montalcini R. Nerve growth factor-induced transformation of immature chromaffin cells in vivo into sympathetic neurons: effect of antiserum to nerve growth factor. Proc Natl Acad Sci U S A. 1979;76(3):1246-1250.
4. Levi-Montalcini R. Trophic, tropic and transforming effects of the nerve growth factor on its target cells. Bull Mem Acad R Med Belg. 1979;134(4):217-228.
5. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer’s disease. Curr Alzheimer Res. 2009;6(2):158-170.
6. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11(5):551-555.
7. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci. 2008;9(3):169-181.
8. Berry A, Bindocci E, Alleva E. NGF, brain and behavioral plasticity. Neural Plast. 2012;2012:784040.
9. Qu HC, Zhang W, Yan S, Liu YL, Wang P. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One. 2014;9(9):e106321.
10. Aloe L, Alleva E, Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol Biochem Behav. 2002;73(1):159-166.
11. Horowitz MA, Zunszain PA, Anacker C, Musaelyan K, Pariante CM. Glucocorticoids and inflammation: a double-headed sword in depression? How do neuroendocrine and inflammatory pathways interact during stress to contribute to the pathogenesis of depression? Mod Trends Pharmacopsychiatri. 2013(28)127-143.
12. Schulte-Herbrüggen O, Chourbaji S, Müller H, et al. Differential regulation of nerve growth factor and brain-derived neurotrophic factor in a mouse model of learned helplessness. Exp Neurol. 2006;202(2):404-409.
13. Schulte-Herbrüggen O, Fuchs E, Abumaria N, et al. Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J Neurosci Res. 2009;87(11):2551-2560.
14. Della FP, Abelaira HM, Réus GZ, et al. Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats. Metab Brain Dis. 2013;28(1):93-105.
15. Cirulli F, Alleva E, Antonelli A, Aloe L. NGF expression in the developing rat brain: effects of maternal separation. Brain Res Dev Brain Res. 2000;123(2):129-134.
16. Emanuele E, Politi P, Bianchi M, Minoretti P, Bertona M, Geroldi D. Raised plasma nerve growth factor levels associated with early-stage romantic love. Psychoneuroendocrinology. 2006;31(3):288-294.
17. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64(6):527-532.
18. Bersani G, Iannitelli A, Fiore M, Angelucci F, Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med Hypotheses. 2000;55(3):199-207.
19. Kapczinski F, Frey BN, Kauer-Sant’Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother. 2008;8(7):1101-1113.
20. Hadjiconstantinou M, McGuire L, Duchemin AM, Laskowski B, Kiecolt-Glaser J, Glaser R. Changes in plasma nerve growth factor levels in older adults associated with chronic stress. J Neuroimmunol. 2001;116(1):102-106.
21. Friden PM, Walus LR, Watson P, et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science. 1993;259(5093):373-377.
22. Pallavi P, Sagar R, Mehta M, et al. Serum neurotrophic factors in adolescent depression: gender difference and correlation with clinical severity. J Affect Disord. 2013;150(2):415-423.
23. Barbosa IG, Huguet RB, Neves FS, et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J Biol Psychiatry. 2011;12(3):228-232.
24. Xiong P, Zeng Y, Wu Q, et al. Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration. J Clin Psychiatry. 2014;75(8):e794-e801.
25. Bilgen AE, Bozkurt Zincir S, Zincir S, et al. Effects of electroconvulsive therapy on serum levels of brain-derived neurotrophic factor and nerve growth factor in treatment resistant major depression. Brain Res Bull. 2014;104:82-87.
26. Brunoni AR, Machado-Vieira R, Zarate CA Jr, et al. Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:91-96.
27. Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Gattaz WF, Forlenza OV. Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry. 2013;21(5):493-496.
28. Martino M, Rocchi G, Escelsior A, et al. NGF serum levels variations in major depressed patients receiving duloxetine. Psychoneuroendocrinology. 2013;38(9):1824-1828.
29. Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, et al. Serum neurotrophins - a study on the time course and influencing factors in a large old age sample. Neurobiol Aging. 2007;28(9):1436-1445.
30. de Azevedo Cardoso T, Mondin TC, Wiener CD, et al. Neurotrophic factors, clinical features and gender differences in depression. Neurochem Res. 2014;39(8):1571-1578.
31. Liu X, Zhang T, He S, et al. Nerve growth factor variations in patients with mood disorders: no changes in eight weeks of clinical treatment. Neuropsychiatr Dis Treat. 2014;10:835-840.
32. Otsuki K, Uchida S, Watanuki T, et al. Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res. 2008;42(14):1145-1153.
33. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry. 2008;41(2):66-71.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
36. Grønli O, Stensland GØ, Wynn R, Olstad R. Neurotrophic factors in serum following ECT: a pilot study. World J Biol Psychiatry. 2009;10(4):295-301.
37. Liu X, Zhang T, He S, et al. Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res. 2014;218(1-2):54-60.
38. Kandratavicius L, Monteiro MR, Assirati JA, Carlotti CG, Hallak JE, Leite JP. Neurotrophins in mesial temporal lobe epilepsy with and without psychiatric comorbidities. J Neuropathol Exp Neurol. 2013;72(11):1029-1042.
39. Banerjee R, Ghosh AK, Ghosh B, Bhattacharyya S, Mondal AC. Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: An analysis in human postmortem brain. Clin Med Insights Pathol. 2013;6:1-11.
40. Kim YK, Na KS, Hwang JA, et al. High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker? J Affect Disord. 2013;151(2):738-743.
41. Fontenelle LF, Barbosa IG, Luna JV, Rocha NP, Silva Miranda A, Teixeira AL. Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res. 2012;199(3):195-200.
42. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol. 2013;28(1):87-90.
43. Secolin R, Banzato CE, Mella LF, Santos ML, Dalgalarrondo P, Lopes-Cendes I. Refinement of chromosome 3p22.3 region and identification of a susceptibility gene for bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(2):163-168.
44. Lester KJ, Hudson JL, Tropeano M, et al. Neurotrophic gene polymorphisms and response to psychological therapy. Transl Psychiatry. 2012;2:e108.
45. Cui D, Zhang H, Yang BZ, et al. Variation in NGFB is associated with primary affective disorders in women. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(4):401-412.
46. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry. 2010;11(6):763-773.
47. Faure J, Uys JD, Marais L, Stein DJ, Daniels WM. Early maternal separation followed by later stressors leads to dysregulation of the HPA-axis and increases in hippocampal NGF and NT-3 levels in a rat model. Metab Brain Dis. 2006;21(2-3):181-188.
48. Cirulli F, Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol. 2009;30(3):379-395.
49. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001;49(5):391-404.
50. Aisa B, Gil-Bea FJ, Marcos B, et al. Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: involvement of the HPA axis. Psychoneuroendocrinology. 2009;34(10):1495-1505.
51. Chaldakov G. The metabotrophic NGF and BDNF: an emerging concept. Arch Ital Biol. 2011;149(2):257-263.
52. Ali TK, Al-Gayyar MM, Matragoon S, et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia. 2011;54(3):657-668.
53. Bersani G, Iannitelli A, Massoni E, et al. Ultradian variation of nerve growth factor plasma levels in healthy and schizophrenic subjects. Int J Immunopathol Pharmacol. 2004;17(3):367-372.
54. Hassanzadeh P, Rahimpour S. The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology (Berl). 2011;215(1):129-141.
55. Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents. 2012;26(3):347-356.
56. Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res. 2006;82(1):95-106.